Erasca, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for ERAS, updated each market day.
ERAS AI Sentiment
AI sees no strong directional signal for Erasca, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Erasca, Inc. Common Stock
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
Sector
Exchange
Market Cap
$5,395,480,135
Cap Tier
Employees
103
Headquarters
SAN DIEGO, CA
Listed Since
July 16, 2021
Website
ERAS Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
ERAS Volatility
Erasca, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
